Latest
News

Edinburgh: Nov 2018

NuCana Reports Third Quarter 2018 Financial Results and Provides Business Update

Edinburgh: Nov 2018

NuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer

Edinburgh: Oct 2018

NuCana Presents Data from Phase I Study of NUC-3373 at ESMO 2018

Past Releases

Edinburgh: November 2018

NuCana to Participate in Citi's 2018 Global Healthcare Conference

Edinburgh: November 2018

NuCana Participated in the 2018 Evercore ISI HealthCONx Conference

Edinburgh: November 2018

NuCana Participated in the Jefferies 2018 London Healthcare Conference

Edinburgh: October 2018

NuCana Reports Additional Promising Clinical Data on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer at ESMO 2018

Edinburgh: October 2018

NuCana Presented New Data from its ProTide Portfolio at the European Society for Medical Oncology (ESMO) 2018 Congress

Edinburgh: August 2018

NuCana Participated in Citi's 13th Annual Biotech Conference.

Edinburgh: August 2018

NuCana Reports Second Quarter 2018 Financial Results and Provides Business Update
Additional Acelarin and NUC-3373 Data to be Presented at ESMO in October

Edinburgh: May 2018

NuCana CEO Hugh Griffith Honoured with the Outstanding Achievement Award From Life Sciences Scotland NuCana also awarded Investment of the Year at awards gala in Glasgow.

Edinburgh: May 2018

NuCana Announces Appointment of Cyrille Leperlier to its Board of Directors

Edinburgh: May 2018

NuCana Reports First Quarter 2018 Financial Results

New York: May 2018

NuCana plc to participate in the Jefferies 2018 Global Healthcare Conference, Thursday 7 June 2018

Edinburgh: April 2018

NuCana plc Announces Appointment of Adam George to its Board of Directors

Edinburgh: March 2018

NuCana Reports Financial Results for the Year Ended December 31, 2017

Edinburgh: March 2018

NuCana to participate in the Cowen and Company 38th Annual Health Care Conference, Boston, MA

Edinburgh: January 2018

NuCana Announces Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin®) as Front-line Treatment of Advanced Biliary Tract Cancer

Edinburgh: November 2017

NuCana plc to participate in the Evercore ISI Biopharma Catalyst / Deep Dive Conference

Edinburgh: November 2017

NuCana Announces First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer

Edinburgh: November 2017

NuCana plc Presented at the Jefferies 2017 London Healthcare Conference

Edinburgh: October 2017

NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters’ Option to Purchase Additional ADSs

Edinburgh: September 2017

NuCana plc Announces Pricing of Initial Public Offering

Edinburgh: September 2017

NuCana announces interim data from First-In-Human Study of transformative anti-cancer agent, NUC-3373 and received Best Poster Presentation Award at ESMO 2017

Edinburgh: September 2017

NuCana announces positive results of NUC-1031 (Acelarin®) in advanced ovarian cancer at ESMO 2017

Boston: March 2017

NuCana presented at the Cowen & Company 37th Annual Healthcare Conference, Boston, Tuesday 7th March 2017, 12.00-12.25pm

New York: February 2017

NuCana participated in the LEERINK Partners 6th Global Healthcare Conference, New York, NY, 15th and 16th February 2017

San Francisco: January 2017

Hugh S. Griffith, CEO presented at the 35th Annual J.P. Morgan Healthcare Conference, San Francisco, January 10th 2017.

Chicago: June 2016

NuCana’s Acelarin achieves high clinical activity and durable disease control in patients with recurrent ovarian cancer

Edinburgh: March 2016

NuCana’s Chief Scientific Officer, Professor Chris McGuigan

Boston: November 2015

NuCana presents exciting data on novel anticancer agent, NUC-3373, at the AACR-NCI-EORTC conference in Boston.

Edinburgh: July 2015

NuCana appoints Professor Chris McGuigan as Chief Scientific Officer.

Chicago: May 2015

NuCana presents ground-breaking final results of the first in human Phase I/II study with Acelarin in advanced solid tumours at the ASCO 51st Annual Meeting.

Chicago: May 2015

Acelarin achieves very high disease control rates in patients with advanced gynaecological cancers in a Phase I/II setting. Study results presented at the ASCO 51st Annual Meeting.

Philadelphia: April 2015

NuCana presents data on the Molecular Diagnostics programme for Acelarin at the AACR Annual Meeting.

Edinburgh: December 2014

NuCana appoints Dr. Paolo Paoletti to its board of Directors.

Chicago: May 2014

Acelarin achieves high disease control rate in patients with advanced cancer.ProGem1 study results presented at the ASCO 50th Annual Meeting.

Edinburgh: April 2014

NuCana announces a Series B financing of $57 million to fund expansion of clinical studies with its anti-cancer ProTides.

San Diego: April 2014

NuCana presents exceptional data for anti-cancer agent, Acelarin, at the AACR Annual Meeting.

San Diego: March 2014

NuCana to present at AACR in San Diego, April 2014.

Edinburgh: February 2014

Important Results of NuCana’s lead ProTide published in prominent scientific journal.

Edinburgh: September 2013

NuCana to attend ESMO 2013 in Amsterdam on 27th September 2013.

Edinburgh: July 2013

NuCana highlight EvaluatePharma report valuing the industries pipeline products. ProTide technology takes number one position.

Cardiff: June 2013

'Drug hunter' Chris McGuigan on NuCana and medical research excitement.

Chicago: June 2013

Encouraging results from the ProGem1 study of Acelarin (NUC-1031) in patients with advanced cancer presented at ASCO 2013.

Edinburgh: May 2013

NuCana to present Phase I clinical data at ASCO 2013 in Chicago on 3rd June 2013.

Edinburgh: April 2013

NuCana Invited to Present at BioEquity Europe on Wednesday 22nd May 2013.

Edinburgh: April 2013

NuCana Appoints Erwan Lejeune as Scientific Affairs Manager.

Edinburgh: March 2013

NuCana to Present at BioTrinity on Wednesday 15th May 2013

Edinburgh: February 2013

NuCana Ups and Downs of a Drug Hunter - from the Lab to Patients.

A lecture by Prof. Chris McGuigan as part of the 'Science in Health' public lecture series at Cardiff University.

Edinburgh: February 2013

NuCana - Pioneering pair invest in a healthy future.

Edinburgh: February 2013

NuCana Biomed announced as joint winners of the Investment of the Year (2012) Award.

Edinburgh: February 2013

NuCana joint winners of the Investment of the Year (2012) Award, download the press release.

Edinburgh: May 2012

NuCana announces the appointment of Ian Abercrombie as Chief Operating Officer.

Edinburgh: November 2011

NuCana secures $10.4 million Series A Financing to accelerate it's ProTide Anti-Cancer Drugs into Clinical Development.

International: November 2011

NuCana Gets $10.5M for ProTide Cancer Drugs.

Scotland: November 2011

Life Science specialists £6.7m for new venture.

Wales: November 2011

Welsh scientists could prevent cancer cells becoming resistant to drugs.

Edinburgh: February 2011

NuCana announced it had completed a further equity financing that will enable NuCana's first product to enter clinical development.

Edinburgh: February 2011

Hugh Griffth to be the Keynote Speaker at the prestigious Scottish Enterprise Life Sciences Annual Dinner on 3rd February 2011.

Cardiff: January 2011

Chris Wood to present at Cardiff University EPSRC/PRESIDENTS ENTREPRENEURSHIP DAY on "Discovering New Medicines & Making Money".

Edinburgh: December 2010

NuCana announces the appointment of Martin Mellish as Non Executive Director to the Board of Directors.

Edinburgh: June 2010

Hugh Griffith guest speaker at BIA & Ernst & Young 'Beyond Borders' Seminar.

Edinburgh: May 2010

Hugh Griffith provides vision for challenges facing Biotechnology in the foreword to Marks & Clerk Life Sciences Report 2010.

Cardiff: April 2010

Christopher Wood to present at Wales Cancer Conference in Cardiff, 14th - 15th April 2010.

Edinburgh: February 2010

Hugh Griffith to present at BIA Scotland BioLeadership Forum and Dinner, 4th February 2010.

Edinburgh: December 2009

NuCana Completes Financing to Expand Anti-Cancer Drug Development Programme.

Edinburgh: December 2009

Alida Capital International Completes Financing into NuCana BioMed.

Cardiff: November 2009

Morvus Technology and NuCana sign exclusive world-wide licence to develop ProTide Technology in Cancer.

In The Media

The Scotsman: April 2018

NuCana plc wins in two catergories at the Scottish Life Science Awards 2018

The Herald: September 2017

Scots firm behind pioneering cancer treatments floats for £75 million

BQ2: October 2016

Scotland Special Report

Labiotech: June 2016

12 European Biotechs which “stole the show” at World most Important Cancer Meeting

Scrip: July 2015

ProTide man Chris McGuigan hopes to make NuCana the next Gilead.

Bioworld Today: June 2015

NuCana set to follow “groundbreaking” ASCO data with phase III trial.

NuCana readies suite of phase III cancer trials after rounding up mid-phase data.

ASCO: May 2015

Watch Professor Sarah Blagden talk about Acelarin at the ASCO (American Society of Clinical Oncology) 51st Annual Meeting.

Financial Times: September 2014

Europe struggles to catch US biotech bulls.

BioCentury: April 2014

Sofinnova Ventures led NuCana BioMed Ltd.’s $57 million B round.

BioWorld: April 2014

High tide for protides: Nucana Biomed pulls in $57M series B.

BBC News - Scotland Business: April 2014

Funding boost for life sciences firm NuCana BioMed.

Venturewire: April 2014

Sofinnova Ventures Leads $57M Financing for NuCana BioMed.

Edinburgh: February 2013

NuCana joint winners of the Investment of the Year (2012) Award, watch NuCana's short film of the award ceremony.

What's happening...

Jefferies logo

London: November 2018

NuCana plc presented at the Jefferies 2018 London Healthcare Conference

Past Events

Munich: October 2018

NuCana Presented New Data from its ProTide Portfolio at the European Society for Medical Oncology (ESMO) 2018 Congress

Boston: September 2018

NuCana Participated in Citi’s 13th Annual Biotech Conference

New York: June 2018

NuCana plc participated in the Jefferies 2018 Global Healthcare Conference, 7 June 2018

Chicago: June 2018

NuCana plc presented data at ASCO 2018 Annual Meeting, 1-5 June 2018

New York: May 2018

NuCana plc participated in the William Blair Late-Stage Therapeutics Conference, 3 May 2018

Boston: March 2018

NuCana plc participated in the Cowen & Company 38th Annual Healthcare Conference, 12-14th March 2018

San Francisco: January 2018

NuCana presented promising clinical data at ASCO GI on NUC-1031 (Acelarin®) as front-line treatment of Advanced Biliary Tract Cancer

London: November 2017

NuCana plc presented at the Jefferies 2017 London Healthcare Conference, London, Wednesday 15th November 2017

Boston: March 2017

NuCana presented at the Cowen & Company 37th Annual Healthcare Conference, Boston, Tuesday 7th March 2017

New York: February 2017

NuCana participated in the LEERINK Partners 6th Global Healthcare Conference, New York, NY, 15th and 16th February 2017

San Francisco: January 2017

Hugh S. Griffith, CEO presented at the 35th Annual J.P. Morgan Healthcare Conference, San Francisco, January 10th 2017

Tokyo: October 2016

Hugh S. Griffith, CEO of NuCana, presented at the 9th annual Japan Biopharma Partnering Conference in Tokyo, 25 October 2016

Boston: September 2016

Hugh S. Griffith, CEO of NuCana, presented at Citi's 11th annual Biotech Conference in Boston, 8 September 2016

Chicago: June 2016

NuCana presented at the American Society of Clinical Oncology in Chicago, 6 June 2016

New Orleans: April 2016

NuCana presented at the American Association for Cancer Research Conference in New Orleans, 16 April 2016

New York: April 2016

NuCana presented at the Needham Healthcare Conference in New York, 12 April 2016

Edinburgh: March 2016

NuCana presented at Scotsman Life Sciences Conference in Edinburgh, 1 March 2016

New York: February 2016

NuCana presented at Leerink Partners Global Healthcare Conference in New York, 10 February 2016

San Francisco: January 2016

Hugh S. Griffith, CEO of NuCana, presented at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, 13 January 2016

New York: December 2015

NuCana’s CEO, Hugh S. Griffith, presented at the 27th annual Piper Jaffray Healthcare Conference in New York, 2 December 2015

Boston: November 2015

NuCana presented NUC-3373 data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, 7 November 2015

Tokyo: October 2015

Hugh S. Griffith, NuCana’s CEO, presented at Japan Biopharma Partnering Conference in Tokyo, 27 October 2015

Cardiff: September 2015

Hugh S. Griffith presented at Tenovus Cancer Care & Life Sciences Research Network Wales Conference at the Life Sciences Hub in Cardiff Bay, 15 September 2015

Chicago: May 2015

NuCana presented results from Acelarin Phase I/II study at the 51st Annual Meeting of the American Society of Clinical Oncology in Chicago, 30 May 2015

Philadelphia: April 2015

NuCana presented Acelarin molecular profiling data at the American Association for Cancer Research Annual Meeting in Philadelphia,
21 April 2015

New York: March 2015

Hugh S. Griffith, NuCana’s CEO, presented at JMP Securities Life Sciences Conference in New York, 27 March 2015

Edinburgh: January 2015

Hugh S. Griffith, NuCana’s CEO, interviewed by BBC, 26 January 2015